Key clinical point: Galcanezumab reduces weekly cluster headache attack frequency.
Major finding: Mean weekly attack frequency decreased by 8.7 days in the galcanezumab group.
Study details: An eight-week, double-blind, placebo-controlled trial of 106 patients with episodic cluster headache.
Disclosures: Eli Lilly and Co. sponsored the study, and Dr. Dodick has a consulting relationship with the company.
Bardos JN et al. AAN 2019. Abstract 02.004.